Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2019 Oct;104(10):e470-e473.
doi: 10.3324/haematol.2019.216804. Epub 2019 Mar 7.

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs

Bruno Fattizzo  1 , Raffaella Pasquale  1 , Monica Carpenedo  2 , Silvia Cantoni  3 , Giuseppe Auteri  4 , Doriana Gramegna  5 , Mariella D'Adda  5 , Mariasanta Napolitano  6 , Dario Consonni  7 , Marco Ruggeri  8 , Sergio Siragusa  6 , Giuseppe Rossi  5 , Nicola Vianelli  4 , Wilma Barcellini  9
Affiliations
Clinical Trial

Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs

Bruno Fattizzo et al. Haematologica. 2019 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Predictors of response and of relapse-free survival in patients treated with thrombopoietin analogs (TPOa). (A) Percentage of responders and non-responders according to bone marrow features or previous treatment. (B) Relapse-free survival (months) by Kaplan-Meyer method according to bone marrow megakaryocytes, lymphoid infiltrate, and reticulinic fibrosis. The following hazard ratios emerged: 2.58 (95%CI: 0.61-10.8) for T-cell infiltrate and 4.24 (95%CI: 1.38-13) for mixed infiltrate versus no or B-cell infiltrate, and 1.82 (95%CI: 0.68-4.86) for bone marrow fibrosis grade 1 (MF1).
See this image and copyright information in PMC

References

    1. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338-4345. - PubMed
    1. Wang L, Li Y, Hou M. Idiopathic thrombocytopenic purpura and dysmegakaryocytopoiesis. Crit Rev Oncol Hematol. 2007;64(2):83-89. - PubMed
    1. Rodeghiero F, Carli G. Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists. Ann Hematol. 2017;96(9):1421-1434. - PubMed
    1. Gonzalez-Porras JR, Bastida JM. Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Ther Adv Drug Saf. 2018;9(6):263-285. - PMC - PubMed
    1. Mazza P, Minoia C, Melpignano A. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a “real life” retrospective multicenter experience of the Rete Ematologica Pugliese (REP). Ann Hematol. 2016;95(2):239-244. - PubMed

MeSH terms

LinkOut - more resources